Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Coronary Artery Disease, Myocardial Ischemia
Interventions: AngioSculpt Scoring Balloon Catheter; Device
Lead sponsor: AngioScore, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer of Head and Neck, Neoplasms, Head and Neck
Interventions: Erlotinib, Green Tea Polyphenon E; Drug · Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland

Conditions: Atrial Fibrillation, Post-Op Complication
Interventions: CardiaMend in Combination with Amiodarone; Combination Product
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions: Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone; Device · Combination Product
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more

Conditions: Nicotine Dependence, Opiate Dependence
Interventions: Intensive, tailored intervention, NJ Quitline Referral; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Plaque-type Psoriasis
Interventions: Placebo, Secukinumab 150mg, Secukinumab 300mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more

Conditions: Arteriosclerosis, Coronary Artery Disease, Myocardial Ischemia, Coronary Disease
Interventions: CrossBoss Catheter, Antegrade Wire Escalation Strategy; Procedure
Lead sponsor: North Texas Veterans Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Boston, Massachusetts • Detroit, Michigan • Minneapolis, Minnesota + 8 more

Conditions: Back Pain Lower Back Chronic
Interventions: Buprenorphine, Oxycodone Immediate-Release; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 85
States / cities: Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 72 more

Conditions: Gastric Atrophy, Gastric Intestinal Metaplasia, Dysplasia, Gastric Adenocarcinoma, Gastric Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2036
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Pyoderma Gangrenosum
Interventions: Spesolimab; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Neuroblastoma
Interventions: hu14.18-Interleukin-2 fusion protein; Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 69
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 61 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Methylphenidate Transdermal System (MTS), placebo patch; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 65 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metastatic Breast Cancer
Interventions: AlloStim, Cryoablation; Biological · Procedure
Lead sponsor: Mirror Biologics, Inc.; Industry
Eligibility: 18 Years to 70 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Stroke
Interventions: Device: 3T scanner with MRI-compatible robot; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Biliary Tract Cancer, Cholangiocarcinoma
Interventions: Gemcitabine, Cisplatin, Durvalumab, Spatially Fractionated RT, Deep Hyperthermia; Drug · Radiation · Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Smoking, Smoking Cessation
Interventions: Nicotine patch, Nicotine gum, CMAC; Drug · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Seattle, Washington • Madison, Wisconsin

Conditions: Major Depressive Disorder, Nicotine Dependence, Depression
Interventions: Fluoxetine, Dextrose; Drug
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Cardiovascular Risk Reduction
Interventions: Estradiol 100 Micrograms Patch, Estradiol Patch; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Liver Neoplasms
Interventions: perflutren lipid microspheres; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Vitiligo
Interventions: Abatacept; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cognitive Impairment Associated With Schizophrenia
Interventions: Nicotine patch, MK-4334, Placebo patch, Placebo capsule; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Long Beach, California • Marlton, New Jersey

Conditions: Skin Cancer
Interventions: DermDx; Device
Lead sponsor: MetaOptima Technology Inc.; Industry
Eligibility: Not listed
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: North Augusta, South Carolina

Conditions: Renal Carcinoma, Renal Mass
Interventions: Robot-Assisted Laparoscopic Surgery, High-Intensity Focused Ultrasound Ablation, Therapeutic Laparoscopic Surgery, Sonatherm 600i Ultrasonic Lesion Generating System; Procedure · Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Chronic Pain, Lower Back Pain Chronic
Interventions: PNS Injectrode F1; Device
Lead sponsor: Neuronoff, Inc; Industry
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Dayton, Ohio

Search by objective public record fields.

AngioSculpt® Coronary Bifurcation Study

Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck

Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

Developing a Smoking Cessation Intervention for Methadone Maintained Smokers

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

A Study Collecting Health Information to Understand and Prevent Gastric Cancer

Spesolimab in Pyoderma Gangrenosum

hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD

Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients

Correlation Analysis Between Brain Lesions and Sensorimotor Impairments in Individuals With Stroke (Preliminary Study)

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines

Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms

Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women

Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation

Open-label Pilot Study of Abatacept for the Treatment of Vitiligo

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

Multi-Center Study to Evaluate the Performance of DermDx for Primary Care Physicians in the Detection of Skin Cancers

Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small Kidney Masses Undergoing Surgery

Lumbar Injectrode Feasibility Evaluation